Announcement

Collapse
No announcement yet.

Progression without Relapses - Drug Trial

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Progression without Relapses - Drug Trial

    MS Specialist to Lead Trial of Temelimab in Progressing Disease Without Relapses

    “It is evident that currently available disease modulatory therapies for MS exert very limited effects on the progressive aspect of MS, and that this phase starts early in the disease course. A role of pHERV-W Env in progressive disease worsening is supported by accumulating preclinical and clinical evidence,” Piehl said in the release.

    https://multiplesclerosisnewstoday.c...le-sclerosis/?
    PPMS for 26 years (dx 1998)
    ~ Worrying will not take away tomorrow's troubles ~ But it will take away today's peace. ~

    #2
    Thanks for this. It's about time!
    I hope the next trial brings us some positive results!
    1st sx '89 Dx '99 w/RRMS - SP since 2010
    Administrator Message Boards/Moderator

    Comment


      #3
      Hey KoKo!

      Thanks for putting a smile in my face Thanksgivings Eve! No facetiousness, really!

      Enjoy tomorrows dinner and all the fixings too!!

      Jer

      Comment


        #4
        Originally posted by 502E79 View Post
        Hey KoKo!

        Thanks for putting a smile in my face Thanksgivings Eve! No facetiousness, really!

        Enjoy tomorrows dinner and all the fixings too!!

        Jer
        Thank you Jer!

        Hope you enjoy Thanksgiving as well.
        PPMS for 26 years (dx 1998)
        ~ Worrying will not take away tomorrow's troubles ~ But it will take away today's peace. ~

        Comment


          #5
          Thank you for posting this KoKo, and Happy Thanksgiving everyone. There are so many PwMS who progress w/o relapses and this trial will be important.

          Just to provide some background on temelimab…

          There is a good bit of info about this drug in the Charcot Project thread. It is a new drug and looks exceptionally effective, so far. I am thrilled that it will be trialed in progressive MS. Early in 2019 this drug was named ‘temelimab’, prior to that it was called GNbAC1, so in the Charcot Project thread GNbAC1 and temelimab are the same drug.

          The two year “Angel” study involved 3 different doses… 18mg per kg of body weight, 12mg/kg, and 6mg/kg. 18mg was the most effective dose, making it the likely dose used in this new study.

          I wish to highlight below one paragraph in particular from a 2019 press release and let it speak for itself because this drug is a game changer in that it allows your body to rebuild myelin by neutralizing the pHERV-W virus and blocking neurodegeneration! Surely, everyone can recognize the implications to MSers of rebuilding myelin!

          QUOTE… “GeNeuro CEO Jesús Martin-Garcia said: “We are extremely pleased with this data, which clearly confirm the robust and consistent effects of temelimab on key MRI markers of neuroprotection, and we are excited by the early signs of clinical benefit.

          “The results of ANGEL-MS confirm the potential of temelimab to act against disease progression, the largest unmet medical need in this indication. It further reinforces our determination to continue the development of temelimab in MS.”

          Temelimab is a humanised, monoclonal antibody designed to mitigate the effect of a certain human endogenous retrovirus (HERV) called pHERV-W, which is found in the brains of MS patients. Neutralising the virus allows the drug to block the neurodegenerative process and restore myelin integrity in MS patients.

          The drug was well-tolerated by the trial participants and there were no dose-limited safety signals." End Quote

          Oh my, it does appear that viral components may be driving MS as hypothesized by the Charcot Project presented at MS World in 2012. I will post there to bump that thread for anyone new interested in more details.

          Comment

          Working...
          X